drugset
drugset / Trial / NCT06247956

Study of SHR-8068 Combined With Adebrelimab and Platinum-containing Chemotherapy in the Treatment of Advanced Gastric and Esophageal Cancer

NCT06247956 ↗

Phase 2 Active not recruiting 153 enrolled Suzhou Suncadia Biopharmaceuticals Co., Ltd.
RandomizedFactorialOpen-labelTreatment

Summary

Objective response rate (ORR) was evaluated to evaluate the efficacy of SHR-8068 combined with adebrelimab and platinum-containing chemotherapy in first-line treatment of advanced gastric and esophageal cancer.

Timeline

Start
2024-03-11
Primary completion
2025-12-30
Completion
2025-12-30

Drugs

EvaluationDrugModalityDoseRoute
Subject SHR-8068 Monoclonal antibody — —
Background Adebrelimab Monoclonal antibody — —
Background Capecitabine Small molecule — —
Background Cisplatin Other / unclassified — —
Background Oxaliplatin Small molecule — —
Background Paclitaxel Small molecule — —

Indications

digestive system carcinoma